Skip to main content
Erschienen in: European Journal of Pediatrics 1/2003

01.12.2003 | Article

Long-term outcome of patients with urea cycle disorders and the question of neonatal screening

verfasst von: Claude Bachmann

Erschienen in: European Journal of Pediatrics | Sonderheft 1/2003

Einloggen, um Zugang zu erhalten

Abstract

With regard to the principles established for neonatal population screening, the question arises whether for patients with urea cycle disorders there is an accepted treatment which really affects the disease course and prognosis as compared to the natural history of these diseases. A retrospective study of 88 patients was performed. Based on questionnaires, the survival rate and neurodevelopmental outcome of patients treated with protein restriction alone was compared to the new therapy introduced in the 1980s with added citrulline/arginine, essential amino acids for improving the amino acid composition of the restricted natural protein and benzoate. Survival of patients with neonatal presentation was improved by the extensive therapy but this mostly at the cost of an increasing number of retarded patients. Long-term outcome did not differ significantly between the two treatments. Of all patients, 56% were symptomatic within 4 days of age and 67% within the 1st week. Thus a prevention of irreversible damage by neonatal screening on blood obtained at 3–4 days of life is questionable. Whether the benefit of obtaining a rapid diagnosis, e.g. for allowing proper counselling and prospective treatment, is acceptable for the parents of prospective patients remains open. The organisation of a dense network of specialised metabolic centres with sufficient staff and resources is a prior condition for any screening programme in order to ensure the rapid diagnosis, follow-up of treatment and counselling of a cumulative number of affected chronic patients needing this support. A commitment on a long-term basis by the institutions is needed in view of the health budget restrictions. Conclusion: in the short term, the goal is to detect hyperammonaemic patients as early as possible with special emphasis on sick neonates. In practice, quantitative plasma ammonia determination without delay is recommended in any newborn for whom a sepsis work-up is considered and in children who refuse feeding or vomit and show alterations of consciousness and/or neurological symptoms.
Fußnoten
1
It is still unknown if the amenorrhoea/menstrual dysfunction which occurred in 23% of the menstruating patients treated with phenylbutyrate as reported by Wiech et al. [14] was due to this drug or to other causes like inadequate protein supply.
 
Literatur
1.
Zurück zum Zitat Bachmann C (1990) Urea cycle disorders. In: Fernandes J, Saudubray J, Tada K (eds) Inborn metabolic diseases: diagnosis and treatment. Springer, Berlin Heidelberg New York, pp 211–228 Bachmann C (1990) Urea cycle disorders. In: Fernandes J, Saudubray J, Tada K (eds) Inborn metabolic diseases: diagnosis and treatment. Springer, Berlin Heidelberg New York, pp 211–228
2.
Zurück zum Zitat Bachmann C (2003) Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr 162: 410–416PubMed Bachmann C (2003) Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr 162: 410–416PubMed
3.
Zurück zum Zitat Bearn AG, Cusworth DC, Dean G, Frézal JP, Neifakh SA, Scheinberg IH, Scriver CR, Szeinberg A (1968) Screening for inborn errors of metabolism. WHO Tech Rep Ser 401: 1–57 Bearn AG, Cusworth DC, Dean G, Frézal JP, Neifakh SA, Scheinberg IH, Scriver CR, Szeinberg A (1968) Screening for inborn errors of metabolism. WHO Tech Rep Ser 401: 1–57
4.
Zurück zum Zitat Bickel H, Bachmann C, Beckers R, Brandt NJ, Clayton BE, Corrado G, Feingold HJ, Giardini O, Hammersen G, Schoenberg D (1981) Neonatal mass screening for metabolic disorders. Eur J Pediatr 137: 133–139 Bickel H, Bachmann C, Beckers R, Brandt NJ, Clayton BE, Corrado G, Feingold HJ, Giardini O, Hammersen G, Schoenberg D (1981) Neonatal mass screening for metabolic disorders. Eur J Pediatr 137: 133–139
5.
Zurück zum Zitat Brusilow SW, Horwich AL (2001) Urea cycle enzymes. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, vol II. McGraw-Hill, New York, pp 1909–1963 Brusilow SW, Horwich AL (2001) Urea cycle enzymes. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, vol II. McGraw-Hill, New York, pp 1909–1963
6.
Zurück zum Zitat Maestri NE, Hauser ER, Bartholomew D, Brusilow SW (1991) Prospective treatment of urea cycle disorders. J Pediatr 119: 923–928PubMed Maestri NE, Hauser ER, Bartholomew D, Brusilow SW (1991) Prospective treatment of urea cycle disorders. J Pediatr 119: 923–928PubMed
7.
Zurück zum Zitat Maestri NE, Clissold DB, Brusilow SW (1995) Long-term survival of patients with argininosuccinate synthetase deficiency. J Pediatr 127: 929–935PubMed Maestri NE, Clissold DB, Brusilow SW (1995) Long-term survival of patients with argininosuccinate synthetase deficiency. J Pediatr 127: 929–935PubMed
8.
Zurück zum Zitat Maestri NE, Brusilow SW, Clissold DB, Bassett SS (1996) Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 335: 855–859 Maestri NE, Brusilow SW, Clissold DB, Bassett SS (1996) Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 335: 855–859
9.
Zurück zum Zitat Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED (1984) Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med 310: 1500–1505 Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED (1984) Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med 310: 1500–1505
10.
Zurück zum Zitat Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, Nicholl J, Nicholson P, Tunaley JR, Virdi NK (1997) Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1: 1–202 Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, Nicholl J, Nicholson P, Tunaley JR, Virdi NK (1997) Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1: 1–202
11.
Zurück zum Zitat Saudubray JM, Touati G, Delonlay P, Jouvet P, Narcy C, Laurent J, Rabier D, Kamoun P, Jan D, Revillon Y (1999) Liver transplantation in urea cycle disorders. Eur J Pediatr 158[Suppl 2]: S55–S59 Saudubray JM, Touati G, Delonlay P, Jouvet P, Narcy C, Laurent J, Rabier D, Kamoun P, Jan D, Revillon Y (1999) Liver transplantation in urea cycle disorders. Eur J Pediatr 158[Suppl 2]: S55–S59
12.
Zurück zum Zitat Tluczek A, Mischler EH, Farrell PM, Fost N, Peterson NM, Carey P, Bruns WT, McCarthy C (1992) Parents’ knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr 13: 181–186PubMed Tluczek A, Mischler EH, Farrell PM, Fost N, Peterson NM, Carey P, Bruns WT, McCarthy C (1992) Parents’ knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr 13: 181–186PubMed
13.
Zurück zum Zitat Uchino T, Endo F, Matsuda I (1998) Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis 21[Suppl 1]: 151–159 Uchino T, Endo F, Matsuda I (1998) Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis 21[Suppl 1]: 151–159
14.
Zurück zum Zitat Wiech N, Clissold D, MacArthur R (1997) Safety and efficacy of buphenyl (sodium phenylbutyrate) tablet and powder (abstract). Advances in Inherited Urea Cycle Disorders, Vienna, Austria, pp 25 Wiech N, Clissold D, MacArthur R (1997) Safety and efficacy of buphenyl (sodium phenylbutyrate) tablet and powder (abstract). Advances in Inherited Urea Cycle Disorders, Vienna, Austria, pp 25
15.
Zurück zum Zitat Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. Public Health Papers WHO 34: 26–39 Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. Public Health Papers WHO 34: 26–39
16.
Zurück zum Zitat Yudkoff M, Daikhin Y, Ye X, Wilson JM, Batshaw ML (1998) In vivo measurement of ureagenesis with stable isotopes. J Inherit Metab Dis 21: 21–29CrossRefPubMed Yudkoff M, Daikhin Y, Ye X, Wilson JM, Batshaw ML (1998) In vivo measurement of ureagenesis with stable isotopes. J Inherit Metab Dis 21: 21–29CrossRefPubMed
Metadaten
Titel
Long-term outcome of patients with urea cycle disorders and the question of neonatal screening
verfasst von
Claude Bachmann
Publikationsdatum
01.12.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Pediatrics / Ausgabe Sonderheft 1/2003
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-003-1347-z

Weitere Artikel der Sonderheft 1/2003

European Journal of Pediatrics 1/2003 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.